手术时RANTES浓度与接受前交叉韧带重建患者术后僵硬相关
前瞻性纳入接受前交叉韧带(ACL)重建的患者,术前收集滑液,回顾性识别因术后僵硬需麻醉下手法松解(MUA)和/或粘连松解(LOA)的病例,按1:2匹配对照。RANTES浓度在需MUA/LOA组显著高于对照组(694.20 pg/mL vs 113.04 pg/mL,P=0.034),单生物标志物模型中RANTES(OR 2.28)和bFGF(OR 1.91)与术后僵硬风险增加相关。
要点
- 需MUA/LOA组滑液RANTES浓度显著高于对照组(P=0.034)。
- 单生物标志物模型中RANTES(OR 2.28)和bFGF(OR 1.91)与术后僵硬风险增加相关。
- IL-6、VEGF-A、TIMP-1、IL-1RA、MMP-3、MCP-1、MIP-1B与术后关节纤维化无关。
核心结论
- 滑液中bFGF和RANTES浓度较高与ACL重建后需干预的僵硬风险增加相关。
- IL-6、VEGF-A、TIMP-1、IL-1RA、MMP-3、MCP-1和MIP-1B与术后关节纤维化发生无关。
研究设计与样本
- 病例对照研究,证据等级3。
- 前瞻性纳入接受ACL重建的患者,术前收集滑液。
- 回顾性识别因术后僵硬需MUA和/或LOA的病例,按1:2匹配对照。
- 共11例病例(男3例,女8例)匹配21例对照(男6例,女15例),年龄、性别、吸烟史、受伤至手术天数无显著差异。
- 采用风险因素调整的单生物标志物模型和多变量模型评估滑液生物标志物与需MUA/LOA的术后僵硬的关联,并使用逐步logistic回归控制临床风险因素。
主要发现
- 需MUA/LOA组RANTES浓度为694.20 pg/mL(四分位距214.75-3428.79),对照组为113.04 pg/mL(四分位距32.81-517.91),组间差异P=0.034。
- 单生物标志物模型中,RANTES的OR为2.28(95%CI 1.29-5.37,P=0.019),bFGF的OR为1.91(95%CI 1.07-3.99,P=0.047),均与ACL重建后需MUA/LOA的术后僵硬风险增加相关。
- 逐步logistic回归识别出3种可能的术后僵硬预测生物标志物纳入最终模型:IL-1RA(P=0.198)、bFGF(P=0.157)、RANTES(P=0.046)。
- IL-6、VEGF-A、TIMP-1、IL-1RA、MMP-3、MCP-1和MIP-1B与术后关节纤维化发生无关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients undergoing anterior cruciate ligament (ACL) reconstruction have been shown to be at risk for postoperative arthrofibrosis. Diagnostic biomarkers associated with the development of postoperative stiffness are unknown. HYPOTHESIS: Biomarkers found in the synovial fluid at the time of surgery are associated with the development of postoperative arthrofibrosis in a cohort of patients undergoing ACL reconstruction. STUDY DESIGN: Case-control study; Level of evidence, 3. METHODS: Patients undergoing ACL reconstruction were prospectively enrolled. Synovial fluid was collected before surgical incision. A cohort of patients with postoperative stiffness requiring manipulation under anesthesia (MUA) and/or lysis of adhesions (LOA) was retrospectively identified. Matching of cases to controls was performed using a 1:2 pair matching algorithm. Risk factor-adjusted single-biomarker and multivariable models were used to assess the association of synovial fluid biomarkers with postoperative stiffness requiring MUA/LOA. Stepwise logistic regression controlling for clinical risk factors was used to identify biomarkers that are possible predictors of postoperative stiffness. RESULTS: A total of 11 cases (3 male, 8 female) were identified and matched with 21 controls (6 male, 15 female) with no significant differences in age, sex, smoking history, or days from injury to surgery. Concentrations of the biomarker regulated upon activation, normal T-cell expressed and presumably secreted (RANTES) were significantly higher in patients requiring MUA/LOA versus controls (694.20 pg/mL [interquartile range, 214.75-3428.79] vs 113.04 pg/mL [interquartile range, 32.81-517.91], respectively; P = .034). On single-biomarker models, RANTES (odds ratio, 2.28; 95% CI, 1.29-5.37; P = .019) and basic fibroblast growth factor (bFGF) (odds ratio, 1.91; 95% CI, 1.07-3.99; P = .047) were associated with increased risk of postoperative stiffness requiring MUA/LOA after ACL reconstruction. Stepwise logistic regression identified 3 biomarkers that are possible predictors of postoperative stiffness, which were included in the final model: Interleukin 1 receptor antagonist (IL-1RA) (P = .198), bFGF (P = .157), and RANTES (P = .046). CONCLUSION: Higher concentrations of synovial fluid biomarkers bFGF and RANTES were associated with increased risk for stiffness requiring intervention after ACL reconstruction. Interleukin 6 (IL-6), vascular endothelial growth factor A (VEGF-A), tissue inhibitor of metalloproteinases 1 (TIMP-1), interleukin 1 receptor antagonist (IL-1RA), matrix metalloproteinase 3 (MMP-3), monocyte chemotactic protein 1 (MCP-1), and macrophage inflammatory protein 1B (MIP-1B) were not associated with the development of postoperative arthrofibrosis.
引用
- Avila A, Petrera M, Duenes M, et al. RANTES Concentration at the Time of Surgery Is Associated With Postoperative Stiffness in Patients Undergoing ACL Reconstruction. Am J Sports Med. 2022. PMID: 36349932. doi:10.1177/03635465221131805
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。